Ph.D.Supervisor
Email:qianben@ibms.pumc.edu.cn
Qianben Wang, Ph.D., Doctoral Supervisor, Tenured Professor, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences / School of Basic Medicine, Peking Union Medical College. He received his Ph.D. from the University of Maryland, Baltimore in 2002 and conducted postdoctoral research at the Dana-Farber Cancer Institute, Harvard Medical School from 2003 to 2008, where he also served as an Instructor. He subsequently held faculty positions at The Ohio State University College of Medicine, serving as Assistant Professor (tenure-track) in the Department of Molecular and Cellular Biochemistry, Associate Professor (tenured) in the Departments of Molecular and Cellular Biochemistry as well as Cancer Biology and Genetics, and later as a tenured Professor and Endowed Chair in the Department of Pathology at Duke University School of Medicine. In August 2025, he returned to China full-time to join the Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences, and the School of Basic Medicine, Peking Union Medical College.
Professor Wang has long focused on gene regulatory mechanisms and RNA-targeted therapeutic strategies in human diseases, making systematic contributions to the transcriptional and epigenetic regulation of hormone-dependent cancers. In recent years, he has integrated CRISPR/Cas13 RNA editing with lipid nanoparticle delivery to establish an “RNA precision therapeutic platform,” achieving advances in addressing cancer metastasis, drug resistance, immune evasion, and lung repair following coronavirus infection. His research has been published in leading international journals including Cell, Molecular Cell, Nature Genetics, Nature Chemical Biology, Cell Research, PNAS, Nature Communications, EMBO Journal, Cancer Research, Advanced Science, and Nano Research.
He currently serves as a Director at Large and Executive Committee Member of the Society for Basic Urologic Research (SBUR), and Chair of its 33rd Annual Meeting in 2025. He previously served as a standing member of the NIH Gene Regulation in Cancer (GRIC) Study Section and as a member of the Duke University School of Medicine Clinical Sciences Appointments, Promotion, & Tenure Committee. He has led multiple NIH U54 and R01 grants as well as Department of Defense (DoD) research projects.
PUBLICATIONS
1. Cui Z, Huang F, Fang K, Yan J, Zhang Y, Kang DD, Zhou Y, Zhao Y, Everitt JI, Hankey W, Armstrong AJ, Huang J, Wang H, Jin VX, Dong Y* and Wang Q*. SCORT-Cas13d nanotherapy precisely targets the ‘undruggable’ transcription factor HoxB13 in metastatic prostate cancer in vivo. Advanced Science, 2025 May 11:e2417605. doi: 10.1002/advs.202417605. Online ahead of print. (*Corresponding authors)
2. Huang F, Li K, Shevach JW and Wang Q. Emerging Therapies to Overcome Antiandrogen Resistance and Beyond in Lethal Prostate Cancer (invited review article). Journal of the National Cancer Center, 2025, https://doi.org/10.1016/j.jncc.2025.04.004.
3. Cui Z, Liu T, Bacon R, Zhao Y, Everitt JI, Yan J, Chen L, Wang H, Dong Y*, Jin VX*, Liu SL*, and Wang Q*. Single-dose cathepsin L CRISPR nanotherapy mitigates PASC-like lung damage in hamsters. Nano Research, 2025, https://doi.org/10.26599/NR.2025.94907695 (*Corresponding authors)
4. Zhou BR, Feng H, Huang F, Zhu I, Shi D, Zaret KS, Landsman D, Wang Q, and Bai Y. Structural insights for the cooperative nucleosome recognition and chromatin opening by FoxA1 and GATA4. Molecular Cell, 2024 Aug 22;84(16):3061-3079.e10. doi: 10.1016/j.molcel.2024.07.016.
5. Cui Z, Zeng C, Huang F, Yuan F, Yan J, Zhao Y, Zhou Y, Hankey W, Jin VX, Huang J, Staats HF, Everitt JI, Sempowski GD, Wang H, Dong Y*, Liu SL* and Wang Q*. Cas13d knockdown of lung protease Ctsl prevents and treats lethal SARS-CoV-2 infection. Nature Chemical Biology, 2022 Oct;18(10):1056-1064. doi: 10.1038/s41589-022-01094-4. (* Corresponding authors).
6. Li T, Liu Q, Chen Z, Fang K, Huang F, Fu X, Wang Q*, and Jin VX*. Dynamic nucleosome landscape elicits a novel noncanonical GATA2 pioneer model. Nature Communications, 2022 Jun 7;13(1):3145. doi: 10.1038/s41467-022-30960-x. (* Corresponding authors)
7. Chen Z*, Hankey W, Zhao Y, Groth J, Wang H, Huang J, Roeder RG, and Wang Q*. Transcriptional recycling assays identify PAF1 as a driver of RNA Pol II recycling. Nature Communications, 2021 Nov 3;12(1):6318. doi: 10.1038/s41467-021-26604-1. (* Corresponding authors)
8. Huang F, Chen H, Zhu X, Gong T, Li X, Hankey W, Ding D, Wang H, Chen Z*, Wang Q*, and Liu Z*. The oncogenic function of androgen receptor in esophageal squamous cell carcinoma is directed by GATA3. Cell Research, 31:362-365, 2021. doi: 10.1038/s41422-020-00428-y. (* Corresponding authors).
9. Yuan F, Hankey W, Wu D, Wang H, Somarelli J, Armstrong AJ, Huang J, Chen Z, Wang Q. Molecular determinants for enzalutamide-induced transcription in prostate cancer. Nucleic Acids Research, 47: 10104-10114, 2019
10. Chen Z, Wu D, Thomas-Ahner JM, Lu C, Zhao P, Zhang Q, Geraghty C, Yan PS, Hankey W, Sunkel B, Cheng X, Antonarakis ES, Wang QE, Liu Z, Huang THM, Jin VX, Clinton SK, Luo J*, Huang J*, Wang Q*. Diverse AR-V7 cistromes in castration-resistant prostate cancer growth are governed by HoxB13. Proc Natl Acad Sci USA, 115: 6810-6815, 2018. (* Corresponding authors).
11. Chen Z*, Lan X, Wu D, Sunkel B, Ye Z, Huang J, Liu Z, Clinton SK, Jin VX and Wang Q*. Ligand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer. Nature Communications, 6: 8323, 2015 (* Corresponding authors).
12. Chen K, Chen Z, Wu D, Zhang L, Lin X, Su J, Rodriguez B, Xi Y, Xia Z, Chen X, Shi X, Wang Q* and Li W*. Broad H3K4me3 is associated with increased transcription elongation and enhancer activity at tumor-suppressor genes. Nature Genetics, 47: 1149-1157, 2015 (* Corresponding authors).
13. Chen Z, Lan X, Thomas-Ahner JM, Wu D, Liu X, Ye Z, Wang L, Sunkel B, Grenade C, Chen J, Zynger DL, Yan PS, Huang, J, Nephew KP, Huang THM, Lin S, Clinton SK, Li W, Jin VX and Wang Q. Agonist and antagonist switch DNA motifs recognized by human androgen receptor in prostate cancer, EMBO Journal, 34: 502-516, 2015.
14. Wu D, Sunkel B, Chen Z, Li Q, Cassandra G, Ye Z, Ke J, Chen H, Nephew KP, Huang THM, Liu Z, Jin VX and Wang Q. Three-tiered role of the pioneer factor GATA2 in promoting androgen-dependent gene expression in prostate cancer. Nucleic Acids Research, 42: 3607-3622, 2014. (NAR Breakthrough Article).
15. Chen Z, Zhang C, Wu D, Chen H, Rorick A, Zhang X, and Wang Q. Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth. EMBO Journal, 30:2405-2419, 2011.
16. Wang Q*^, Li, W^, Zhang Y, Yuan X, Xu K, Yu J, Chen Z, Beroukhim R, Wang H, Wu T, Lupien M, Carroll JS, Manrai AK, Jänne OA, Balk SP, Mehra R, Chinnaiyan AM, Rubin MA, True L, Fiorentino M, Fiore C, Loda M, Kantoff PW, Liu XS*, and Brown M*. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell, 138:245-256, 2009. (*Corresponding authors, ^ First authors) (Cell Featured Article)